Key statistics
As of last trade, Immunoprecise Antibodies Ltd (TQB:MUN) traded at 0.585, 17.00% above the 52 week low of 0.50 set on Sep 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.585 |
---|---|
High | 0.585 |
Low | 0.585 |
Bid | 0.590 |
Offer | 0.655 |
Previous close | 0.57 |
Average volume | 0.00 |
---|---|
Shares outstanding | 27.30m |
Free float | 23.83m |
P/E (TTM) | -- |
Market cap | 18.43m USD |
EPS (TTM) | -0.7695 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
Press releases
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
- IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
- ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
- ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
- ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
- ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
- ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
- IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
- ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
More ▼